138 related articles for article (PubMed ID: 32239732)
1. X-ray crystal structure localizes the mechanism of inhibition of an IL-36R antagonist monoclonal antibody to interaction with Ig1 and Ig2 extra cellular domains.
Larson ET; Brennan DL; Hickey ER; Ganesan R; Kroe-Barrett R; Farrow NA
Protein Sci; 2020 Jul; 29(7):1679-1686. PubMed ID: 32239732
[TBL] [Abstract][Full Text] [Related]
2. One target-two different binding modes: structural insights into gevokizumab and canakinumab interactions to interleukin-1β.
Blech M; Peter D; Fischer P; Bauer MM; Hafner M; Zeeb M; Nar H
J Mol Biol; 2013 Jan; 425(1):94-111. PubMed ID: 23041424
[TBL] [Abstract][Full Text] [Related]
3. Generation and functional characterization of anti-human and anti-mouse IL-36R antagonist monoclonal antibodies.
Ganesan R; Raymond EL; Mennerich D; Woska JR; Caviness G; Grimaldi C; Ahlberg J; Perez R; Roberts S; Yang D; Jerath K; Truncali K; Frego L; Sepulveda E; Gupta P; Brown SE; Howell MD; Canada KA; Kroe-Barrett R; Fine JS; Singh S; Mbow ML
MAbs; 2017 Oct; 9(7):1143-1154. PubMed ID: 28726542
[TBL] [Abstract][Full Text] [Related]
4. Quantitative ligand and receptor binding studies reveal the mechanism of interleukin-36 (IL-36) pathway activation.
Zhou L; Todorovic V; Kakavas S; Sielaff B; Medina L; Wang L; Sadhukhan R; Stockmann H; Richardson PL; DiGiammarino E; Sun C; Scott V
J Biol Chem; 2018 Jan; 293(2):403-411. PubMed ID: 29180446
[TBL] [Abstract][Full Text] [Related]
5. Structure of CD40 ligand in complex with the Fab fragment of a neutralizing humanized antibody.
Karpusas M; Lucci J; Ferrant J; Benjamin C; Taylor FR; Strauch K; Garber E; Hsu YM
Structure; 2001 Apr; 9(4):321-9. PubMed ID: 11525169
[TBL] [Abstract][Full Text] [Related]
6. Unusual water-mediated antigenic recognition of the proinflammatory cytokine interleukin-18.
Argiriadi MA; Xiang T; Wu C; Ghayur T; Borhani DW
J Biol Chem; 2009 Sep; 284(36):24478-89. PubMed ID: 19553661
[TBL] [Abstract][Full Text] [Related]
7. Structure of a Potential Therapeutic Antibody Bound to Interleukin-16 (IL-16): MECHANISTIC INSIGHTS AND NEW THERAPEUTIC OPPORTUNITIES.
Hall G; Cullen E; Sawmynaden K; Arnold J; Fox S; Cowan R; Muskett FW; Matthews D; Merritt A; Kettleborough C; Cruikshank W; Taylor D; Bayliss R; Carr MD
J Biol Chem; 2016 Aug; 291(32):16840-8. PubMed ID: 27231345
[TBL] [Abstract][Full Text] [Related]
8. Crystal structures of the pro-inflammatory cytokine interleukin-23 and its complex with a high-affinity neutralizing antibody.
Beyer BM; Ingram R; Ramanathan L; Reichert P; Le HV; Madison V; Orth P
J Mol Biol; 2008 Oct; 382(4):942-55. PubMed ID: 18708069
[TBL] [Abstract][Full Text] [Related]
9. Molecular Basis of Selective Cytokine Signaling Inhibition by Antibodies Targeting a Shared Receptor.
Fields JK; Kihn K; Birkedal GS; Klontz EH; Sjöström K; Günther S; Beadenkopf R; Forsberg G; Liberg D; Snyder GA; Deredge D; Sundberg EJ
Front Immunol; 2021; 12():779100. PubMed ID: 35003094
[TBL] [Abstract][Full Text] [Related]
10. VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface.
Muller YA; Chen Y; Christinger HW; Li B; Cunningham BC; Lowman HB; de Vos AM
Structure; 1998 Sep; 6(9):1153-67. PubMed ID: 9753694
[TBL] [Abstract][Full Text] [Related]
11. Structure of IL-17A in complex with a potent, fully human neutralizing antibody.
Gerhardt S; Abbott WM; Hargreaves D; Pauptit RA; Davies RA; Needham MR; Langham C; Barker W; Aziz A; Snow MJ; Dawson S; Welsh F; Wilkinson T; Vaugan T; Beste G; Bishop S; Popovic B; Rees G; Sleeman M; Tuske SJ; Coales SJ; Hamuro Y; Russell C
J Mol Biol; 2009 Dec; 394(5):905-21. PubMed ID: 19835883
[TBL] [Abstract][Full Text] [Related]
12. Structural studies on the folded domain of the human prion protein bound to the Fab fragment of the antibody POM1.
Baral PK; Wieland B; Swayampakula M; Polymenidou M; Rahman MH; Kav NN; Aguzzi A; James MN
Acta Crystallogr D Biol Crystallogr; 2012 Nov; 68(Pt 11):1501-12. PubMed ID: 23090399
[TBL] [Abstract][Full Text] [Related]
13. Structural basis for treating tumor necrosis factor α (TNFα)-associated diseases with the therapeutic antibody infliximab.
Liang S; Dai J; Hou S; Su L; Zhang D; Guo H; Hu S; Wang H; Rao Z; Guo Y; Lou Z
J Biol Chem; 2013 May; 288(19):13799-807. PubMed ID: 23504311
[TBL] [Abstract][Full Text] [Related]
14. Three-dimensional structures of the free and antigen-bound Fab from monoclonal antilysozyme antibody HyHEL-63(,).
Li Y; Li H; Smith-Gill SJ; Mariuzza RA
Biochemistry; 2000 May; 39(21):6296-309. PubMed ID: 10828942
[TBL] [Abstract][Full Text] [Related]
15. Production of a human neutralizing monoclonal antibody and its crystal structure in complex with ectodomain 3 of the interleukin-13 receptor α1.
Redpath NT; Xu Y; Wilson NJ; Fabri LJ; Baca M; Andrews AE; Braley H; Lu P; Ireland C; Ernst RE; Woods A; Forrest G; An Z; Zaller DM; Strohl WR; Luo CS; Czabotar PE; Garrett TP; Hilton DJ; Nash AD; Zhang JG; Nicola NA
Biochem J; 2013 Apr; 451(2):165-75. PubMed ID: 23384096
[TBL] [Abstract][Full Text] [Related]
16. Retrospective analysis of model-based predictivity of human pharmacokinetics for anti-IL-36R monoclonal antibody MAB92 using a rat anti-mouse IL-36R monoclonal antibody and RNA expression data (FANTOM5).
Ahlberg J; Giragossian C; Li H; Myzithras M; Raymond E; Caviness G; Grimaldi C; Brown SE; Perez R; Yang D; Kroe-Barrett R; Joseph D; Pamulapati C; Coble K; Ruus P; Woska JR; Ganesan R; Hansel S; Mbow ML
MAbs; 2019 Jul; 11(5):956-964. PubMed ID: 31068073
[TBL] [Abstract][Full Text] [Related]
17. Mutual conformational adaptations in antigen and antibody upon complex formation between an Fab and HIV-1 capsid protein p24.
Monaco-Malbet S; Berthet-Colominas C; Novelli A; Battaï N; Piga N; Cheynet V; Mallet F; Cusack S
Structure; 2000 Oct; 8(10):1069-77. PubMed ID: 11080628
[TBL] [Abstract][Full Text] [Related]
18. Molecular determinants of agonist and antagonist signaling through the IL-36 receptor.
Günther S; Sundberg EJ
J Immunol; 2014 Jul; 193(2):921-30. PubMed ID: 24935927
[TBL] [Abstract][Full Text] [Related]
19. Structural basis for the blockage of IL-2 signaling by therapeutic antibody basiliximab.
Du J; Yang H; Zhang D; Wang J; Guo H; Peng B; Guo Y; Ding J
J Immunol; 2010 Feb; 184(3):1361-8. PubMed ID: 20032294
[TBL] [Abstract][Full Text] [Related]
20. IL-36 receptor antagonistic antibodies inhibit inflammatory responses in preclinical models of psoriasiform dermatitis.
Su Z; Paulsboe S; Wetter J; Salte K; Kannan A; Mathew S; Horowitz A; Gerstein C; Namovic M; Todorović V; Seagal J; Edelmayer RM; Viner M; Rinaldi L; Zhou L; Leys L; Huang S; Wang L; Sadhukhan R; Honore P; McGaraughty S; Scott VE
Exp Dermatol; 2019 Feb; 28(2):113-120. PubMed ID: 30417427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
